Edgar Filing: Margolis Jeff Eliot

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Margolis Jeff Eliot

2. Issuer Name and Ticker or Trading Symbol
RespireRx Pharmaceuticals Inc. [RSPI]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
SVP, Treas., Sec., CFO

(Last)

(First)

(Middle)

C/O RESPIRERX PHARMACEUTICALS INC, 126 VALLEY ROAD, SUITE C

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2017

(Street)

GLEN ROCK, NJ 07452

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Common Stock Options (to purchase shares of Common Stock)

$ 1.45

12/09/2017

J⁽¹⁾

388,687

⁽¹⁾

12/09/2022

Common Stock

388,687

⁽¹⁾

388,687

Common Stock Options (to purchase shares of Common Stock)

$ 1.45

12/09/2017

G⁽²⁾

250,000

⁽¹⁾

12/09/2022

Common Stock

250,000

$ 0

138,687

Common Stock Options (to purchase shares of Common Stock)

$ 1.45

12/09/2017

G⁽²⁾

250,000

⁽¹⁾

12/09/2022

Common Stock

250,000

$ 0

250,000

By Trust ⁽⁶⁾

Common Stock Options (to purchase shares of Common Stock)

$ 1.45

12/09/2017

G⁽²⁾

100,000

⁽¹⁾

12/09/2022

Common Stock

100,000

$ 0

38,687

Common Stock Options (to purchase shares of Common Stock)

$ 1.45

12/09/2017

G⁽²⁾

100,000

⁽¹⁾

12/09/2022

Common Stock

100,000

$ 0

100,000

By Trusts ⁽⁷⁾

Common Stock Options (to purchase shares of Common Stock)

$ 1.45

12/09/2017

G⁽²⁾

38,687

⁽¹⁾

12/09/2022

Common Stock

38,687

$ 0

Common Stock Options (to purchase shares of Common Stock)

$ 1.45

12/09/2017

G⁽²⁾

38,687

⁽¹⁾

12/09/2022

Common Stock

38,687

$ 0

38,687

By Spouse

Common Stock Options (to purchase shares of Common Stock)

$ 1.45

12/09/2017

G⁽²⁾

38,687

⁽¹⁾

12/09/2022

Common Stock

38,687

$ 0

By Spouse

Common Stock Options (to purchase shares of Common Stock)

$ 1.45

12/09/2017

G⁽²⁾

38,687

⁽¹⁾

12/09/2022

Common Stock

38,687

$ 0

38,687

By Trust ⁽⁹⁾

Common Stock Options (to purchase shares of Common Stock)

$ 2

⁽³⁾

07/26/2022

Common Stock

25,000

Common Stock Options (to purchase shares of Common Stock)

$ 2

⁽⁴⁾

06/30/2022

Common Stock

30,000

By Trust ⁽⁶⁾

Common Stock Options (to purchase shares of Common Stock)

$ 2

⁽⁴⁾

06/30/2022

Common Stock

20,000

By Spouse

Common Stock Options (to purchase shares of Common Stock)

$ 3.9

⁽⁵⁾

01/18/2022

Common Stock

35,000

By Trust ⁽⁶⁾

Common Stock Options (to purchase shares of Common Stock)

$ 3.9

⁽⁵⁾

01/18/2022

Common Stock

15,000

By Trusts ⁽⁷⁾

Warrants (right to buy)

$ 6.9225 ⁽¹⁰⁾

⁽¹¹⁾

09/30/2020

Common Stock

2,423 ⁽¹⁰⁾

2,243 ⁽¹⁰⁾

By Trust ⁽⁶⁾

Warrants (right to buy)

$ 6.9225 ⁽¹⁰⁾

⁽¹¹⁾

09/30/2020

Common Stock

2,423 ⁽¹⁰⁾

By Trusts ⁽⁸⁾

Common Stock Options (to purchase shares of Common Stock)

$ 7.3775 ⁽¹⁰⁾

⁽¹²⁾

03/31/2021

Common Stock

40,000 ⁽¹⁰⁾

By Trust ⁽⁶⁾

Common Stock Options (to purchase shares of Common Stock)

$ 7.3775 ⁽¹⁰⁾

⁽¹²⁾

03/31/2021

Common Stock

6,154 ⁽¹⁰⁾

By Trusts ⁽⁷⁾

Common Stock Options (to purchase shares of Common Stock)

$ 7.3775 ⁽¹⁰⁾

⁽¹²⁾

03/31/2021

Common Stock

21,539 ⁽¹⁰⁾

By Trust ⁽⁹⁾

Common Stock Options (to purchase shares of Common Stock)

$ 7.3775 ⁽¹⁰⁾

⁽¹²⁾

03/31/2021

COmmon Stock

6,154 ⁽¹⁰⁾

By Trusts ⁽⁸⁾

Common Stock Options (to purchase shares of Common Stock)

$ 6.396 ⁽¹⁰⁾

⁽¹³⁾

08/18/2022

Common Stock

13,847 ⁽¹⁰⁾

By Trust ⁽⁶⁾

Common Stock Options (to purchase shares of Common Stock)

$ 6.396 ⁽¹⁰⁾

⁽¹³⁾

08/18/2022

Common Stock

7,693 ⁽¹⁰⁾

By Trusts ⁽⁷⁾

Common Stock Options (to purchase shares of Common Stock)

$ 6.396 ⁽¹⁰⁾

⁽¹³⁾

08/18/2022

Common Stock

7,693 ⁽¹⁰⁾

7,693

By Trust ⁽⁹⁾

Common Stock Options (to purchase shares of Common Stock)

$ 6.396 ⁽¹⁰⁾

⁽¹³⁾

08/18/2022

Common Stock

1,539 ⁽¹⁰⁾

1,538 ⁽¹⁰⁾

By Trusts ⁽⁸⁾

Common Stock Options (to purchase shares of Common Stock)

$ 8.125 ⁽¹⁰⁾

⁽¹⁴⁾

06/30/2022

Common Stock

24,616 ⁽¹⁰⁾

By Trust ⁽⁶⁾

Common Stock Options (to purchase shares of Common Stock)

$ 8.125 ⁽¹⁰⁾

⁽¹⁴⁾

06/30/2022

Common Stock

6,154 ⁽¹⁰⁾

By Trust ⁽⁷⁾

Common Stock Options (to purchase shares of Common Stock)

$ 8.125 ⁽¹⁰⁾

⁽¹⁴⁾

06/30/2022

Common Stock

13,847 ⁽¹⁰⁾

By Trust ⁽⁹⁾

Common Stock Options (to purchase shares of Common Stock)

$ 8.125 ⁽¹⁰⁾

⁽¹⁴⁾

06/30/2022

Common Stock

1,539 ⁽¹⁰⁾

By Trusts ⁽⁸⁾

Common Stock Options (to purchase shares of Common Stock)

$ 16.25 ⁽¹⁰⁾

⁽¹⁵⁾

07/17/2019

Common Stock

6,994 ⁽¹⁰⁾

Common Stock Options (to purchase shares of Common Stock)

$ 16.25 ⁽¹⁰⁾

⁽¹⁵⁾

07/17/2019

Common Stock

8,392 ⁽¹⁰⁾

By Trust ⁽⁶⁾ ⁽⁷⁾ ⁽⁸⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Margolis Jeff Eliot C/O RESPIRERX PHARMACEUTICALS INC 126 VALLEY ROAD, SUITE C GLEN ROCK, NJ 07452	X		SVP, Treas., Sec., CFO

Signatures

/s/ Jeff Eliot Margolis		12/12/2017
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	On December 9, 2017, Mr. Margolis forgave all of the accrued but unpaid compensation to which, pursuant to his employment agreement, he was entitled as of September 30, 2017, an aggregate of $560,876. On that date, the Company granted Mr. Margolis options to purchase 388,687 shares of the Company's common stock, with a black-scholes value of $1.44 per option and an aggregate value of $560,876. These Common Stock Options vested upon issuance.
(2)	These dispositions and acquisitions reflect estate planning transactions. These securities are being contributed to trusts for the benefit of Mr. Margolis, his spouse and his children, as specified.
(3)	These Common Stock Options vested in three installments: 25 percent on July 26, 2017 (the grant date), 25 percent on September 30, 2017, and 50 percent on December 31, 2017.
(4)	These Common Stock Options vested upon issuance.
(5)	These Common Stock Options vested in three installments: 25 percent on January 18, 2017 (the grant date), 25 percent on March 31, 2017, and 50 percent on June 30, 2017, and are all currently vested.
(6)	These securities are held in a trust for the benefit of Mr. Margolis's spouse. Mr. Margolis's spouse is a trustee of the trust.
(7)	These securities are held in trusts for the benefit of Mr. Margolis's children. Mr. Margolis's spouse is a trustee of these trusts. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
(8)	These securities are held in trusts for the benefit of Mr. Margolis's children. Mr. Margolis is a trustee of these trusts. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
(9)	These securities are held in a trust for the benefit of Mr. Margolis. Mr. Margolis is a trustee of the trust.
(10)	The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016.
(11)	These Warrants were acquired by Mr. Margolis and his spouse in his capacity as President of Aurora Capital LLC, which served as placement agent in the Company's unit offering with each unit consisting of one share of common stock and warrants to purchase two additional shares of common stock, and represent his share of the Placement Agent Warrants awarded at each closing of that transaction. The warrants are currently exercisable.
(12)	These Common Stock Options vested in four equal installments: 25 percent on March 31, 2016 (the grant date), 25 percent on June 30, 2016, 25 percent on September 30, 2016, and 25 percent on December 31, 2016, and are all currently vested.
(13)	These Common Stock Options vested in four equal installments: 25 percent on December 31, 2015, 25 percent on March 31, 2016, 25 percent on June 30, 2016, and 25 percent on September 30, 2016, and are all currently vested.
(14)	These Common Stock Options vested in three installments: 50 percent on June 30, 2015, 25 percent on September 30, 2015, and 25 percent on December 31, 2015, and are all currently vested and exercisable.
(15)	These Common Stock Options vested in three equal installments on July 17, 2014, September 30, 2014 and December 31, 2014, and are all currently vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.